The stock has been placed in Enhanced Surveillance Measure (ESM) list ESM - II (35).

Valiant Laboratories Ltd.

NSE: VALIANTLAB

BSE: 543998

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

128.43-2.6 (-2.00%)

23 Oct, 12:00 AM

Income Statement

Abridged

Understanding Income Statement

Valiant Laboratories Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M AR	12M PR	12M AR	12M AR	12M AR	12M IR
Total Revenue	208.24	333.91	182.06	133.38	237.47	305.93
Cost of Operating Revenue	169.15	278.88	170.22	124.55	213.11	233.57
Gross Profit	39.10	55.03	11.84	8.83	24.36	72.36
Gross Margin	18.8	16.5	6.5	6.6	10.3	23.7
Total Operating Expenses	179.71	300.38	192.43	136.90	236.94	281.05
Operating Profit	28.54	33.53	-10.37	-3.52	0.53	24.88
Operating Margin	13.7	10.0	-5.7	-2.6	0.2	8.1
Financing Income/(Expense) - Net	-0.02	-0.16	2.60	2.85	-0.81	-2.90
Profit before Taxes	30.18	38.14	-0.77	-1.51	0.77	24.51
Income Taxes	7.46	9.14	-1.09	0.69	4.04	8.50
Profit after Tax	22.72	29.00	0.32	-2.20	-3.27	16.01
PAT Margin	10.9	8.7	0.2	-1.7	-1.4	5.2
EPS - Basic - ex Extraordinary Items	12.96	8.27	0.08	-0.47	-0.65	3.08
EPS - Diluted - ex Extraordinary Items	12.96	8.27	0.08	-0.47	-0.65	3.08
EBIT	28.54	33.53	-10.37	-3.52	0.53	24.88
EBITDA	30.15	35.09	-8.41	-1.43	6.57	33.25
EBITDA Margin	14.5	10.5	-4.6	-1.1	2.8	10.9

Balance Sheet

Abridged

Understanding Balance Sheet

Valiant Laboratories Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	AR	PR	AR	AR	AR
Total Current Assets	149.72	150.58	225.54	192.62	228.32
Long-Term Investments	1.01	1.23	3.44	3.57	2.41
Property Plant & Equipment - Net	23.67	48.80	92.70	204.11	233.10
Total Non-Current Assets	24.68	62.39	117.14	208.24	235.65
Total Assets	174.41	212.97	342.69	400.86	463.98
Total Current Liabilities	42.02	50.73	29.08	59.62	119.45
Long Term Debt	59.40	60.04	75.09	104.60	28.89
Total Non-Current Liabilities	60.92	61.75	76.75	106.93	33.65
Total Liabilities	102.95	112.47	105.83	166.55	153.09
Total Shareholders' Equity	71.46	100.49	236.86	234.31	310.89
Total Equity	71.46	100.49	236.86	234.31	310.89
Total Liabilities & Equity	174.41	212.97	342.69	400.86	463.98

Cash Flow

Abridged

Understanding Cash Flow Statement

Valiant Laboratories Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M PR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	29.15	30.89	2.18	5.07	4.86
Working Capital - Increase/(Decrease)	-14.43	25.16	-0.37	-3.93	-17.08
Net CF from Operating Activities	14.73	56.05	1.81	1.14	-12.22
Capital Expenditures - Net	5.84	37.68	45.87	113.80	34.17
Net CF from Investing Activities	-15.39	-55.19	-143.88	-52.77	7.25
Stock - Issuance/(Retirement) - Net	48.90	-	135.88	-	10.86
Debt - LT & ST - Issuance/(Retirement) - Total	-28.07	-0.91	16.65	45.15	-76.26
Net Cash Flow from Financing Activities	20.80	-0.91	152.53	44.83	3.58
Free Cash Flow to Equity	-19.18	17.46	-27.41	-67.51	-122.64
Free Operating CF net dividend	8.85	18.37	-44.06	-112.72	-46.42
Free Operating CF	8.85	18.37	-44.06	-112.72	-46.42

Business Segment Analysis

FY End:

Mar 26

Valiant Laboratories Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

chemicals business (100.0%)₹ 34.20 Cr

Revenue / Sales

chemicals business (100.0%)₹ 237.47 Cr

Assets

chemicals business (100.0%)₹ 463.98 Cr

Operating Income

chemicals business (100.0%)₹ 0.53 Cr

Regional Segment Analysis

Valiant Laboratories Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Valiant Laboratories Ltd.

Historical Segment Analysis

Track how Valiant Laboratories Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2025 Mar 31	2026 Mar 31
	2025 Mar 31	2026 Mar 31
chemicals business	114	34

Frequently Asked Questions

What is the revenue of Valiant Laboratories Ltd.?

The latest trailing twelve month revenue of Valiant Laboratories Ltd. is ₹ 305.93 Cr, reflecting a 1-year growth of 89.64% and a 3-year CAGR of -10.74%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Valiant Laboratories Ltd.?

The latest trailing twelve month net profit (PAT) of Valiant Laboratories Ltd. is ₹ 16.01 Cr, with a 3-year earnings CAGR of -27.27%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Valiant Laboratories Ltd.?

The trailing twelve month EBITDA of Valiant Laboratories Ltd. is approximately ₹ 24.89 Cr (based on an operating margin of 8.14%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Valiant Laboratories Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Valiant Laboratories Ltd. is 2.95. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Valiant Laboratories Ltd.?

The debt-to-equity ratio of Valiant Laboratories Ltd. stands at 0.15. The interest coverage ratio is 8.60x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Valiant Laboratories Ltd.?

The estimated book value per share of Valiant Laboratories Ltd. is 57.24 (derived from a P/B ratio of 2.24 and market price of ₹ 128.43), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Valiant Laboratories Ltd.?

The trailing twelve month operating cash flow of Valiant Laboratories Ltd. is ₹ -12.22 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Valiant Laboratories Ltd. report consolidated or standalone financials?

Valiant Laboratories Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.